• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Ultra-hypofractionation in localized prostate cancer. 5-year results of the HYPO-RT-PC trial: Commentary I].

作者信息

Jiang Ping, Blanck Oliver, Dunst Jürgen

机构信息

Universitätsklinik für Medizinische Strahlenphysik, Medizinischer Campus Pius-Hospital, Carl von Ossietzky Universität Oldenburg, Oldenburg, Deutschland.

Klinik für Strahlentherapie, Christian-Albrechts-Universität zu Kiel & Universitätsklinikum Schleswig-Holstein, Kiel, Deutschland.

出版信息

Strahlenther Onkol. 2019 Dec;195(12):1116-1118. doi: 10.1007/s00066-019-01535-5.

DOI:10.1007/s00066-019-01535-5
PMID:31667552
Abstract
摘要

相似文献

1
[Ultra-hypofractionation in localized prostate cancer. 5-year results of the HYPO-RT-PC trial: Commentary I].[局限性前列腺癌的超分割放疗。HYPO-RT-PC试验的5年结果：评论I]
Strahlenther Onkol. 2019 Dec;195(12):1116-1118. doi: 10.1007/s00066-019-01535-5.
2
[Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: HYPO-RT-PC randomized trial. 5-year results: Commentary II].[前列腺癌超分割与常规分割放疗：HYPO-RT-PC随机试验。5年结果：评论II]
Strahlenther Onkol. 2019 Dec;195(12):1119-1121. doi: 10.1007/s00066-019-01536-4.
3
Editorial Comment: Ultra-hypofractionated versus conventionally fractionated radiothe-rapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.编者按：前列腺癌的超分割放疗与常规分割放疗：HYPO-RT-PC随机、非劣效性3期试验的5年结果。
Int Braz J Urol. 2020 Nov-Dec;46(6):1100-1101. doi: 10.1590/S1677-5538.IBJU.2020.06.09.
4
Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial.中高危局限性前列腺癌的中度适形放疗：来自随机、3 期 HYPRO 试验的健康相关生活质量。
Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):823-833. doi: 10.1016/j.ijrobp.2018.11.020. Epub 2018 Nov 17.
5
Comparison of Outcomes and Toxicity Between Extreme and Moderate Radiation Therapy Hypofractionation in Localized Prostate Cancer: A Propensity Score Analysis.极端与中度放疗在局限性前列腺癌中的疗效与毒性比较：倾向评分分析。
Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):735-744. doi: 10.1016/j.ijrobp.2019.07.027. Epub 2019 Aug 1.
6
Leukotoxicity after moderately Hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate Cancer: a secondary analysis from a randomized study.中分割调强放疗与常规分割大剂量递增放疗治疗局限性前列腺癌的血液学毒性：一项随机研究的二次分析。
Radiat Oncol. 2019 Jan 30;14(1):23. doi: 10.1186/s13014-019-1223-2.
7
Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer.局部前列腺癌患者应用内置式直肠气囊的中度低分割调强放疗的长期疗效。
Cancer Commun (Lond). 2018 Apr 17;38(1):11. doi: 10.1186/s40880-018-0281-4.
8
[Effects of hypofractionated radiation therapy for men with localized prostate cancer].
Urologe A. 2020 Aug;59(8):953-956. doi: 10.1007/s00120-020-01262-1.
9
Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer.VMAT 与 3DCRT 在后装治疗前列腺癌术后患者中的应用。
Anticancer Res. 2013 Oct;33(10):4537-43.
10
Are We Now Able to Define Guidelines for Moderate Hypofractionation in Prostate Cancer Radiation Therapy?我们现在是否能够确定前列腺癌放射治疗中适度低分割放疗的指南？
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):871-873. doi: 10.1016/j.ijrobp.2017.12.274.

本文引用的文献

1
Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial.单次分割保留尿道前列腺癌 SBRT：ONE SHOT 试验的 I 期结果。
Radiother Oncol. 2019 Oct;139:83-86. doi: 10.1016/j.radonc.2019.07.018. Epub 2019 Aug 17.
2
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.超分割与常规分割放疗治疗前列腺癌的比较：HYPO-RT-PC 随机、非劣效、III 期临床试验的 5 年结果。
Lancet. 2019 Aug 3;394(10196):385-395. doi: 10.1016/S0140-6736(19)31131-6. Epub 2019 Jun 18.
3
Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.
立体定向体部放射治疗局限性前列腺癌：超过 6000 例前瞻性研究患者的系统评价和荟萃分析。
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):778-789. doi: 10.1016/j.ijrobp.2019.03.051. Epub 2019 Apr 6.
4
Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.立体定向体部放疗治疗低危和中危前列腺癌的长期疗效。
JAMA Netw Open. 2019 Feb 1;2(2):e188006. doi: 10.1001/jamanetworkopen.2018.8006.
5
Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.局部前列腺癌的低分割立体定向体部放疗：一项德国双中心单治疗组可行性试验
Radiat Oncol. 2017 Aug 18;12(1):138. doi: 10.1186/s13014-017-0872-2.
6
Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer.单剂量高剂量率近距离治疗与两三个剂量分次治疗局部晚期前列腺癌的比较。
Radiother Oncol. 2017 Jul;124(1):56-60. doi: 10.1016/j.radonc.2017.06.014. Epub 2017 Jun 27.
7
Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial.中高危局限性前列腺癌的适度分割放疗：III 期随机试验的最终结果。
J Clin Oncol. 2017 Jun 10;35(17):1891-1897. doi: 10.1200/JCO.2016.70.4189. Epub 2017 Mar 29.
8
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.随机分组试验：一种低分割辐射方案治疗局限性前列腺癌。
J Clin Oncol. 2017 Jun 10;35(17):1884-1890. doi: 10.1200/JCO.2016.71.7397. Epub 2017 Mar 15.
9
Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.局部前列腺癌患者的低分割与常规分割放疗（HYPRO）：一项随机、多中心、开放标签、3 期临床试验的最终疗效结果。
Lancet Oncol. 2016 Aug;17(8):1061-1069. doi: 10.1016/S1470-2045(16)30070-5. Epub 2016 Jun 20.
10
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.常规分割与大分割高剂量调强放疗治疗前列腺癌：随机、非劣效性3期CHHiP试验的5年结果
Lancet Oncol. 2016 Aug;17(8):1047-1060. doi: 10.1016/S1470-2045(16)30102-4. Epub 2016 Jun 20.